LifeVantage Corporation reports developments for a health and wellness company built around nutrigenomics, dietary supplements, skin and hair care products, nootropic energy drink mixes, and pet supplements. Its product line includes Protandim, TrueScience Liquid Collagen, MindBody GLP-1 System, LoveBiome P84, AXIO, TrueScience skin and hair care products, and Petandim, sold through independent Consultants to customers.
Company news commonly covers quarterly results, regional sales trends, product innovation, patents tied to cellular-signaling supplement compositions, consultant events and training, international market expansion, executive leadership changes, share repurchases, and cash dividends. Updates also describe capital allocation and the company’s direct-selling business model.
LifeVantage (Nasdaq: LFVN) received U.S. Patent No. 12,589,067 B2 (issued March 31, 2026) for its Healthy Glow Essentials Stack, covering compositions and methods pairing Protandim Nrf2 Synergizer and TrueScience Liquid Collagen.
The patent cites synergistic activation of cellular signaling genes and fibroblast study results supporting skin benefits and broader cellular-health effects, reflecting over three years of the company’s R&D work.
LifeVantage (Nasdaq: LFVN) concluded its three-day Momentum Academy in Las Vegas on April 20, 2026, focused on leadership, product innovation and Consultant empowerment.
Highlights: introduction of two limited-time AXIO flavors, a U.S. patent granted for the Healthy Glow Essentials Stack, renewed Clean Commitment packaging efforts, and a planned CEO transition with Steve Fife retiring April 30 and Terrence Moorehead joining August 5 (with Michael Beindorff as interim CEO).
LifeVantage (Nasdaq: LFVN) announced Terrence Moorehead will become President and CEO, and join the board, effective August 5, 2026. Mr. Moorehead brings 25+ years of direct‑selling and consumer products experience, including leading Nature’s Sunshine where revenue rose 45% and EBITDA 190%.
Steve Fife will retire effective April 30, 2026; an interim team will lead the company until Mr. Moorehead assumes the role.
LifeVantage (Nasdaq: LFVN) will participate in the Water Tower Research Insights Conference on Wednesday, April 15, 2026. Senior management — CEO Steve Fife, CSO Kristen Cunningham, and VP R&D Lisa Barnes — will present. The webcast begins at approximately 12:30 p.m. ET and is open access.
According to the company, investors can register via the investor relations website to access the live webcast and related materials.
LifeVantage (Nasdaq: LFVN) will expand into Portugal with a planned May 2026 launch, offering flagship nutrigenomic products nationwide and introducing its independent Consultant business opportunity.
Initial portfolio includes Protandim Nrf2, Protandim Nrf1, and TrueScience Liquid Collagen; enrollment inquiries directed to ptsupport@lifevantage.com.
LifeVantage (Nasdaq: LFVN) will participate in the Sidoti Small Cap Conference March 18-19, 2026. CEO Steve Fife and CFO Carl Aure will meet virtually with investors and present on March 19, 2026 at ~4:00 p.m. ET.
A live webcast of the presentation will be available on the company’s Investor Relations News & Events page.
LifeVantage (Nasdaq: LFVN) announced a quarterly cash dividend of $0.045 per share, payable March 16, 2026 to shareholders of record at the close of business on March 2, 2026. The Board approved the distribution as a return of capital to common shareholders.
LifeVantage (Nasdaq: LFVN) announced that Steve Fife, President and CEO, will retire in April 2026 after nine years at the company.
Fife will remain in his role during a transition while the Board conducts an extensive executive search and anticipates naming a new CEO in the coming months.
LifeVantage (Nasdaq: LFVN) reported Q2 fiscal 2026 results for the quarter ended Dec 31, 2025: revenue $48.9M (down 27.8% YoY, +2.9% sequential), net income $0.3M or $0.02 diluted, adjusted EPS $0.15, and adjusted EBITDA $3.9M. Gross margin was 74.0% with a $2.4M inventory obsolescence charge tied to MindBody GLP-1. Cash was $10.2M with no debt. The board approved a $60M share repurchase program and declared a $0.045 per-share cash dividend payable Mar 16, 2026. Fiscal 2026 guidance: revenue $185M–$200M; adjusted EBITDA $15M–$19M; adjusted EPS $0.60–$0.80.
LifeVantage (Nasdaq:LFVN) will release second quarter fiscal 2026 results for the quarter ended December 31, 2025 after market close on Wednesday, February 4, 2026. The company will host an investor conference call the same day at 2:30 p.m. Mountain Time (4:30 p.m. Eastern Time) with U.S. dial-in (877) 704-4453 and international dial-in (201) 389-0920.
A telephone replay will be available about two hours after the call and accessible through Wednesday, February 18, 2026 via U.S. replay (844) 512-2921 or international (412) 317-6671 using confirmation code 13757766. A simultaneous live webcast will stream on the Investor Relations site and will be archived for approximately 30 days.